At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play. On ...
The stigmatized idea could get a massive boost from “tech bros”—and some scientists are cheering them on. Brian Armstrong, the billionaire CEO of the cryptocurrency exchange Coinbase, says he’s ready ...
Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results